HLA-DR expression in clinical-grade bone marrow-derived multipotent mesenchymal stromal cells : a two-site study by Grau Vorster, Marta et al.
RESEARCH Open Access
HLA-DR expression in clinical-grade bone
marrow-derived multipotent mesenchymal
stromal cells: a two-site study
Marta Grau-Vorster1,2†, Anita Laitinen3†, Johanna Nystedt3* and Joaquim Vives1,4,5*
Abstract
Background: Contrary to the minimal criteria proposed by the International Society for Cell and Gene Therapy for
defining multipotent mesenchymal stromal cells (MSC), human leukocyte antigen (HLA)-DR expression is largely
unpredictable in ex vivo-expanded clinical-grade cultures. Although activation of MSC in culture does not appear to
affect their functionality, a large study investigating the impact of HLA-DR expression on cell identity and potency is
still missing in the literature.
Methods: A retrospective analysis of HLA-DR expression in 130 clinical batches of bone marrow (BM)-MSC from
two independent Good Manufacturing Practice-compliant production facilities was performed in order to identify
the consequences on critical quality attributes as well as potential activation cues and dynamics of MSC activation
in culture.
Results: HLA-DR+ cells in culture were confirmed to maintain fibroblastic morphology, mesenchymal phenotype
identity, multipotency in vitro, and immunomodulatory capacity. Interestingly, the use of either human sera or
platelet lysate supplements resulted in similar results.
Conclusions: HLA-DR expression should be considered informative rather than as a criterion to define MSC. Further
work is still required to understand the impact of HLA-DR expression in the context of product specifications on
BM-MSC qualities for clinical use in specific indications.
Keywords: Multipotent mesenchymal stromal cell, Potency, Identity, HLA-DR, Cellular therapy, Cell culture, Quality
compliance
Introduction
Multipotent mesenchymal stromal cells (MSCs) can be
easily derived from bone marrow (BM) aspirates and
further expanded ex vivo up to sufficient numbers for
clinical use [1, 2]. Indeed, several clinical applications of
MSC are currently being explored in the fields of trans-
plantation and regenerative medicine, with a couple of
products already holding marketing approval [3–5]. In
addition to their potential to become specialized bone,
cartilage, and fat cells, the use of MSC is of particular
interest in the management of graft rejection and/or in-
flammatory conditions, due to their capacity to modulate
the biological response of other cell types involved in
these processes [6]. In view of their increasing popularity
of MSC as a candidate drug for use in the treatment of a
range of pathologies, the International Society for Cell
and Gene Therapy (ISCT) established minimal criteria
to define MSC identity in an attempt to standardize the
product specifications and methods for characterization
of MSC regardless of their origin and derivation pro-
tocols [7]. ISCT’s criteria are based on MSC’s adherence
to plastic surfaces, multipotency in vitro, and the ex-
pression of a set of cell surface markers (positive for
CD73, CD90, and CD105; negative for CD14, CD34,
CD45 or CD11b, CD79α or CD19, and HLA-DR). Intri-
guingly, BM-MSC do express HLA-DR not only when
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inflammatory molecules such as IFN-γ are present but
also under normal expansion culture conditions [8, 9].
In the present study, we re-analyzed HLA-DR ex-
pression in 130 clinical batches of BM-MSC from two
independent Good Manufacturing Practice (GMP)-com-
pliant production facilities to study its potential effect on
the attributes of MSC and the dynamics of activation in
expansion cultures.
Methods
Cells and cell culture
In Barcelona, clinical-grade BM-MSC were produced
within the context of four clinical trials (2009-016449-
24, 2010-023998-18, 2013-005025-23, 2010-023999-12)
with appropriate donor informed consent and approval
from a competent regulatory authority. When needed,
cells were further expanded in vitro up to sufficient
numbers (always under passage 4) using Dulbecco’s
modified Eagle’s medium (DMEM; Gibco) supplemented
with 10% human serum B (hSerB) containing 2 mM
glutamine in T-flasks and CellSTACKS (Corning Incor-
porated Life Sciences) at 1 × 103 to 3.5 × 103 cells/cm2
seeding density [10]. All cultures were maintained at
37 °C and 5% CO2 in humidified incubators. Cell counting
and viability assessment of BM samples were performed
using a Guava EasyCyte Mini (Millipore).
In Helsinki, donor recruitment, eligibility assessment,
and bone marrow aspiration protocol were approved by
the local ethics committee, and the BM collection pro-
cedure was authorized by the Finnish Medicines Agency
under a tissue establishment license. MSCs were pro-
duced under a national advanced therapy medicinal
products (ATMP) hospital exemption license authorized
by the Finnish Medicines Agency (Fimea; national
ATMP manufacturing licenses #6322/20.10.01/2011 and
#5103/20.30.01/2013). MSC were derived from BM aspi-
rates as reported elsewhere [11]. Briefly, primary cultures
(P0) were initiated by plating isolated BM mononuclear
cells (MNCs) at 4 × 105 cells/cm2. The MSCs were ex-
panded in a medium consisting of Dulbecco’s modified
Eagle’s medium (DMEM) low glucose (Life Technologies)
supplemented with 10% human Platelet Lysate (hPL) and
40 UI/mL heparin (Heparin LEO 5000 IE/KY/mL; Leo
Pharma) [12]. Culture medium was replaced twice a week,
and the cells were detached with TrypLE Select CTS (Life
Technologies). The cells were plated at a density of 1 ×
103 cells/cm2 from P1 onwards.
Phenotype assessment
Immunophenotypic characterization of BM-MSC was
performed using the following antibodies. The Barcelona
protocol used mouse anti-human CD45-fluorescein
isothiocyanate (CD45-FITC, HI30, BD Pharmingen),
anti-human CD105-phycoerythrin (CD105-PE, 43A4E1;
Miltenyi Biotec), anti-human HLA-DR-FITC (L243; BD
Biosciences), anti-human CD90-PE (F15-42-1-5, Beckman
Coulter), mouse anti-human CD31-FITC (WM59; BD
Pharmingen), and mouse anti-human CD73-PE (AD2, BD
Pharmingen). The Helsinki protocol used cell surface anti-
gens CD44 (CD44 –FITC, G44-26; BD Pharmingen),
CD49e (CD49e-PE, IIA1; BD Pharmingen), CD13 (CD13-
APC, WM15; BD Pharmingen), CD90 (CD90-FITC, 5E10;
Stemcell Technologies and BD Pharmingen), CD73
(CD73-PE, AD2; BD Pharmingen), CD29 (CD29-APC,
MAR4; BD Pharmingen), CD105 (CD105-PE, 266, BD
Pharmingen; 43A3, Stem Cell Technologies; and MEM-
229, Abcam), CD14, (CD14-PE, M5E2; BD Pharmingen),
CD19 (CD19-PE, HIB19; BD Pharmingen), CD34 (CD34-
PE, 8G12, BD Biosciences; AC136, Miltenyi Biotec), CD45
(CD45-PE, H130; BD Pharmingen), and HLA-DR (HLA-
DR –PE, MEM-12, Abcam; L243, BD Biosciences).
Cells were stained for 15 min at room temperature
(Barcelona) and for 30 min on ice (Helsinki), washed,
and resuspended in phosphate-buffered saline (DPBS;
Gibco). Non-specific cell staining was ruled out by using
mouse immunoglobulin isotype controls (BD Pharmin-
gen). The acquisition was performed on a FACSCalibur
(Barcelona) or a Navios cytometer (Helsinki), and data
were analyzed with the FlowJo software (TreeStar Inc.,
Ashland, OR, USA).
In both laboratories, HLA-DR expression was analyzed
and used only for informative purposes but not for
product release.
Re-analysis of HLA-DR for the standardization of data
analysis from the two groups was performed using
FlowJo. The gating strategy with the use of IgG isotype
control for unspecific staining (below 1%) is shown in
Additional file 1: Figure S1.
Differentiation assays
Specific differentiation media were used for the osteo-
genic, chondrogenic, and adipogenic induction of undif-
ferentiated MSC cultures in vitro as reported previously
[12–14]. Safranin O (Sigma), Oil Red O (Sigma), Sudan III
(Sigma), and von Kossa (Sigma) stainings were per-
formed for the determination of the outcome of the
differentiation assays.
Cell count, viability, and apoptosis
Cells were counted either by Trypan blue dye exclusion
methods or with Perfect-Count Microspheres (Cytognos)
in a FACSCalibur cytometer (Becton Dickinson). Via-
bility was determined using the 7-amino-actinomycin D
(7-AAD, BD Biosciences) exclusion method and expressed
as a percentage (%) of total cells. Data were analyzed with
the CellQuest Pro (Becton Dickinson) software. Alter-
natively, cell numbers and viability were determined using
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the NucleoCounter NC-100 device (ChemoMetec A/S,
Denmark).
Lymphocyte proliferation assays
The immunomodulation potential of BM-MSC was
tested in the presence of peripheral blood mononuclear
cells (PBMC) at a ratio of 1:5 (Barcelona procedure) and
1:10, 1:20, and 1:50 (Helsinki procedure) as described
elsewhere [12, 15]. The proliferation of carboxyfluores-
cein diacetate succinimidyl ester (CFSE)-labeled PBMC
after polyclonal stimulation was determined by measur-
ing the reduction of fluorescence intensity at day 5 by
flow cytometry.
Effect of different medium supplements
The effect of different medium supplements on the
variation of HLA-DR expression was investigated after
incubation of the same BM-MSC lines with different
batches of sera. For this purpose, three independent
BM-MSC lines were expanded under the same condi-
tions for one passage and subsequently incubated with
either one of two different conditions for an additional
passage: one condition that was previously found experi-
mentally related to activation of BM-MSC (14.3 ± 12.8%
HLA-DR+ cells, n = 7) and another one related to low
HLA-DR+ cell number in culture (3.3 ± 3.3% HLA-DR+
cells, n = 2).
Activation of MSC
For cell activation experiments, IFN-γ (R&D Systems,
Minneapolis, MN, USA) was used as a stimulus at 10,
100, and 200 UI/mL, based on the concentrations used
in previously reported experiments [16].
For the recovery after stimulation experiments, the
same line was used for all three conditions. Cells were
previously stimulated 48 h with 100 UI/mL of IFN-γ.
After 48 h incubation, cells were left without IFN-γ to
see the decrease in HLA-DR. Controls without stimu-
lation at any point and with maintained stimulation with
100 UI/mL of IFN-γ were performed.
Data analysis
Descriptive data were expressed as mean ± standard
deviation. Pearson correlation p values were calculated
to evaluate the significance of the correlation of cell
density and HLA-DR expression in BM-MSC.
Results
BM-MSC express variable levels of HLA-DR
Despite compliance with the ISCT criteria, BM-MSC in
culture showed variable percentages of HLA-DR+ cells in
130 batches produced in two manufacturing sites (namely,
Barcelona, n = 91, and Helsinki, n = 39). HLA-DR ex-
pression in Barcelona batches ranged from < 1 to 77.7%
(average 19.8 ± 15.6%, from patients enrolled in clinical
trials for autologous use), whereas batches in Helsinki
ranged from < 1 to 60.5% (average 19.2 ± 17.4%, from
healthy donors for allogeneic use) (Table 1). In order to
bring consistency to the comparability of analyses per-
formed in different laboratories following different tech-
niques, we reanalyzed a fraction of data from both
laboratories (n = 65 and n = 37 from Barcelona and
Helsinki, respectively; Additional file 1: Figure S2) BM-
MSC batches from both centers complied with the specifi-
cations approved by their own respective regulatory
authority in terms of phenotype, adherence to culture-
treated plastic surfaces, fibroblastic morphology, differen-
tiation potential, and immunomodulation capacity in vitro
(Additional file 1: Table S1, Fig. 1).
In order to determine the potential triggers of cell acti-
vation in culture, standard parameters were analyzed, in-
cluding density, medium supplements, and forced
activation with IFN-γ and its recovery after removal of
the stimulus.
Effect of cell density and passaging on HLA-DR expression
Regarding cell density and HLA-DR expression, no cor-
relation was found (Fig. 2); dispersion without statistical
correlation was observed in both cases (p value = 0.2287
and 0.2272, in Barcelona and Helsinki datasets, respec-
tively). However, culture passaging was found to change
the HLA-DR+ cell percentage. We collected HLA-DR
values from the two passages required in the production
process, which typically take a total of 3 weeks and cor-
respond to 24.6 ± 1.5 cumulative population doublings
(CPD). We observed a decrement in HLA-DR positivity
of at least 25% in 71.9% of the cultures, whereas only
5.3% increased HLA-DR more than 25% of its initial
value (n = 57). Furthermore, one MSC line was cultured
up to passage 5 confirming the decrease in HLA-DR+
cell number (Additional file 1: Figure S3).
Effect of cell culture medium supplement on HLA-DR
expression
Different batches of sera experimentally related with
high and low HLA-DR values were tested in three
BM-MSC lines derived from three different donors.
Table 1 Summary of HLA-DR expression in 130 batches of
clinical-grade BM-MSC from two independent GMP-compliant
facilities. Batches of BM-MSC were distributed according to the
production site







Barcelona 91 19.8 15.6 < 1 77.7
Helsinki 39 19.2 17.4 < 1 60.5
Total 130
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Despite starting with similar HLA-DR values (17.1%,
19.4%, and 15.0%; corresponding to an average of
17.2% ± 2.2%), the percentage of activation after incu-
bation varied independently of the cell line or supple-
ment. Remarkably, none of the other mesenchymal
surface markers depended on HLA-DR expression
(Table 2). Additionally, the potentiality of the three
cell lines was not altered in either case, showing a
similar capacity to differentiate in vitro into the
osteogenic and chondrogenic lineages (Additional file 1:
Figure S4).
Activation of HLA-DR expression
We took advantage of IFN-γ being a strong activator of
MSC in vitro and performed a series of experiments to
study the effect of its addition to determine the kinetics
of BM-MSC activation upon stimulation with increasing
doses of IFN-γ. We observed that the maximum acti-
vation was reached at 48 h after induction, resulting in
high levels of activation when using 100 and 200 UI/mL
doses (Fig. 3a). Interestingly, when IFN-γ stimulus was
removed, the number of HLA-DR+ cells decreased
gradually over time (Fig. 3b).
Fig. 1 Differentiation and immunomodulation potential of BM-MSC. Selected examples of characterization assays performed on BM-MSC at
Barcelona’s and Helsinki’s facilities. a Differentiation potential was confirmed by von Kossa staining after 4-week culture in osteogenic medium
(black depositions), Oil Red O/Sudan III staining after 3-week culture in adipogenic medium (lipid droplets in the cytoplasm of adipocytes stained
red), and Safranin O staining after 3-week culture in chondrogenic medium (glycosaminoglycans stained red). b Immunomodulatory properties
of MSC were tested by means of the lymphocyte proliferation assay, in which MSC demonstrated their capacity to suppress proliferation of
polyclonally stimulated lymphocytes. Barcelona scale bars = 200 μm. Helsinki von Kossa scale bars = 500 μm and Oil Red O scale bars = 100 μm
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Discussion
Variability of HLA-DR expression in MSC cultures is a
nuisance for developers adhering to the criteria estab-
lished by the ISCT, so it tends to be overlooked provided
that quality control (QC) panels are adapted to robust
product specifications in order to bring consistency from
batch to batch using reliable markers [17]. This makes it
difficult to fully realize how different cell preparations
from different production sites can be. In this context,
standardization of QC criteria and methodology is a
pressing need as new MSC-based therapies reach the
clinical setting and comparability of studies is required
to define the efficacy of such new drug candidates [4, 5].
In the present study, we focused on the analysis of HLA
class II molecule expression in cultured MSC which was
demonstrated to be unpredictable and dynamic over time
thus confirming previous studies [8]. Expression of
HLA-DR has been proved, both in the present work
and reported by others, that it can be triggered in
vitro by IFN-γ [9, 18] and other pro-inflammatory stimuli
[19]. Interestingly, when IFN-γ stimulus was removed, the
number of HLA-DR+ cells gradually decreased over time.
This observation is relevant since HLA-DR expression on
cells during expansion cultures is variable over time; how-
ever, in-process and final product quality controls are per-
formed only at specific time points during the production
process, typically after 8 to 10 days from seeding, there-
fore showing only a snapshot of the status of the cells
and as a result could be potentially masking a dy-
namic pattern of expression of HLA-DR. Regardless of
HLA-DR, the identity of MSC is clearly defined by other
parameters, such as the presence of mesenchymal cell sur-
face markers and absence of hematopoietic and endothe-
lial markers, fibroblastic cell morphology on plastic
surfaces, and immunomodulation and differentiation po-
tential [7]. Indeed, we also showed that HLA-DR expres-
sion had no effect on immunomodulation and
multilineage differentiation potential of MSC [8].
In one of the first reports on this topic, Le Blanc and
collaborators analyzed the intracellular protein levels of
HLA-DR in MSC in parallel with extracellular HLA-DR
phenotype by flow cytometry [18]. They found that MSC
Fig. 2 Analysis of cell culture parameters. Effect of cell density on HLA-DR expression was studied in batches released from both manufacturing
sites, namely Barcelona (a) and Helsinki (b). However, high dispersion without statistical correlation was observed in both cases (p value = 0.2287
and 0.2272, respectively)
Table 2 Result summary after expanding cells in different medium formulations associated with “activating” or “neutral” cues.
Activation of cells occurred randomly regardless of the supplement used. Nonetheless, differentiation potential was not altered
(please refer to Additional file 1: Figure S2)
Cell line Passage number supplement %CD31 %CD45 %HLA-DR %CD73 %CD105 %CD90
1 P0 3.6 1.9 17.1 99.8 99.9 99.83
P1 Activating 2.0 0.3 14.2 99.7 99.9 99.6
P1 Neutral 7.7 2.0 29.6 99.3 99.4 99.4
2 P0 6.4 1.1 19.4 100 98.7 99.9
P1 Activating 8.4 3.0 37.7 99.7 99.6 99.9
P1 Neutral 7.6 3.3 40.9 99.8 99.5 99.9
3 P0 7.2 1.0 15.0 99.7 99.7 99.84
P1 Activating 4.7 3.3 23.9 99.4 99.4 99.5
P1 Neutral 4.3 2.9 25.4 99.1 99.3 99.3
P passage number
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expressed first HLA-DR at the protein level intracellu-
larly, and only later HLA-DR molecules were detected in
the cellular membrane upon activation. The intracellular
synthesis of HLA-DR was initiated after 2 days of expo-
sure to IFN-γ, but required up to 7 days for cell surface
expression. Nevertheless, we detected MSC activation
extracellularly after 48 h after IFN-γ exposure and pro-
vided data of slow HLA-DR downregulation. With this,
it seems clear from these studies that the expression of
HLA-DR can come from a previous exposure since
clinical-grade manufacture bioprocesses are relatively
short (that is, two passages only) and we provided evi-
dence of variability of HLA-DR expression even in the
very first passage. One might think that the condition of
the donor could determine MSC activation in culture;
however, our study collected data from both healthy
donors and patients, and in both cases, the occurrence
of HLA-DR expression appeared to be random.
With the removal of HLA-DR expression of MSC
from the QC panels, and the acceptance that HLA-DR
expression in cultured MSC does not follow a predic-
table pattern under standard in vitro growth conditions,
it would be interesting to further investigate its triggers as
its expression is known to be indicative of inflammatory
microenvironments and maybe also differentiation com-
mitment [20]. In any case, the major concern regarding
HLA-DR expression in MSC would be the potential rejec-
tion of these cells. Lately, new hypotheses about the MSC
mechanisms of action involved are being proposed, and
among them, efferocytosis is gaining strength. This hypoth-
esis supports that MSC releases soluble molecules and
extracellular macrovesicles that signal to the target environ-
ment and then disappear [6]. Without considering HLA-
DR expression, MSCs have not been reported to cause
rejection, but on the contrary, MSCs are being used in the
management of graft-versus-host disease (GvHD) [21, 22].
The mechanisms by which these cells induce tolerance
were reported by Galleu and collaborators in vivo in an
animal model and were apoptosis of MSC resulted in the
induction of immunosuppression [23]. Interestingly, IFN-γ-
activated MSCs are being used for the treatment of GvHD
to induce tolerance [9]. Moreover, Zachar and collaborators
illustrated that MSCs have to be activated in order to pro-
vide their therapeutic effects in the regenerative medicine
field [19]. Therefore, the presence of HLA-DR molecules
on the cell surface does not compromise MSC identity,
Fig. 3 Dynamics of BM-MSC activation in vitro. In culture, BM-MSC are activated by the addition of IFN-γ, which is illustrated by increasing
concentration up to 200 UI/mL, reaching a peak 48 h after stimulation (a). Interestingly, the reversal of the process for the recovery of HLA-DR
expression levels using IFN-γ-activated cells takes longer than the activation time (b)
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neither their function and application in the clinical setting
for immunomodulation and differentiation potential appli-
cations. Further clinical studies could discard the secondary
effects of activated MSC as well as their therapeutic effect.
Conclusions
We concluded that the use of HLA-DR as a negative
marker of BM-MSC does not add any additional value to
QC panels and its expression does not affect other attri-
butes, such as phenotype and functionality in vitro. Further-
more, we showed for the first time that the expression of
HLA-DR is dynamic in MSC cultures. Finally, we believe
that we can only reliably describe the full clinical potential
of MSC if robust QC panels directly related to MSC’s func-
tionality are characterized, so the definition and broad
adoption of meaningful potency assays are urgently needed.
Additional file
Additional file 1: Table S1. Release criteria of clinical-grade batches of
BM-MSC from two independent GMP-compliant facilities. Release criteria
defined on MSC phenotype. Figure S1. Gating strategy used in flow
cytometry analysis to determine HLA-DR expression in BM-MSC.
Represented in blue IgG isotype control for unspecific staining. The interval
gate was established with a value of HLA-DR+ of isotype control positivity
below 1%. Figure S2. Comparison of HLA-DR covariance between batch
release and after standardization of the analysis of cytometric data from
Barcelona and Helsinki. Statistically not significant (p value 0.2997).
Figure S3. Percentage of MSC expressing HLA-DR along culture
passaging. Figure S4. Osteogenic and chondrogenic potential of cells
cultured in the presence of activating and non-activating sera supplements.
Scale bars = 200 μm. (DOCX 16212 kb)
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